Analysts Set Theravance Biopharma, Inc. (NASDAQ:TBPH) Target Price at $13.75

Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) has been assigned an average recommendation of "Hold" from the five research firms that are currently covering the firm, Marketbeat.com reports. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $13.75.

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $15.00 price objective on shares of Theravance Biopharma in a research note on Tuesday, February 25th.

Insider Buying and Selling

In other news, SVP Rhonda Farnum sold 4,000 shares of the firm's stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $9.00, for a total transaction of $36,000.00. Following the completion of the sale, the senior vice president now directly owns 309,565 shares in the company, valued at $2,786,085. This trade represents a 1.28 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 6.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Theravance Biopharma

Hedge funds have recently bought and sold shares of the business. Newtyn Management LLC grew its position in shares of Theravance Biopharma by 5.7% during the fourth quarter. Newtyn Management LLC now owns 4,757,403 shares of the biopharmaceutical company's stock worth $44,767,000 after buying an additional 258,337 shares in the last quarter. BNP Paribas Financial Markets raised its stake in shares of Theravance Biopharma by 88.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 305,480 shares of the biopharmaceutical company's stock valued at $2,462,000 after purchasing an additional 143,781 shares in the last quarter. Algert Global LLC bought a new position in shares of Theravance Biopharma during the third quarter worth about $851,000. Dimensional Fund Advisors LP grew its stake in Theravance Biopharma by 20.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 553,713 shares of the biopharmaceutical company's stock worth $5,211,000 after purchasing an additional 95,304 shares in the last quarter. Finally, Millennium Management LLC increased its holdings in Theravance Biopharma by 71.1% in the fourth quarter. Millennium Management LLC now owns 192,839 shares of the biopharmaceutical company's stock valued at $1,815,000 after buying an additional 80,140 shares during the last quarter. Institutional investors and hedge funds own 99.10% of the company's stock.

Remove Ads

Theravance Biopharma Stock Performance

Theravance Biopharma stock traded down $0.01 during trading on Friday, reaching $9.30. The company had a trading volume of 157,314 shares, compared to its average volume of 288,319. Theravance Biopharma has a 12-month low of $7.44 and a 12-month high of $10.90. The stock's 50 day moving average price is $9.36 and its two-hundred day moving average price is $9.08. The firm has a market capitalization of $460.08 million, a price-to-earnings ratio of -9.21 and a beta of 0.15.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.26). Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. The company had revenue of $18.75 million for the quarter, compared to analysts' expectations of $29.90 million. As a group, research analysts expect that Theravance Biopharma will post -1.09 earnings per share for the current year.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.